As of May 29, 2025, Zosano Pharma Corp (ZSAN) reports a ROE (Return on Equity) of -90.75%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Zosano Pharma Corp's ROE (Return on Equity)
Over recent years, Zosano Pharma Corp's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2021-12-31 | -90.75% |
| 2020-12-31 | -70.22% |
| 2019-12-31 | -400.32% |
| 2018-12-31 | -188.99% |
| 2017-12-31 | -412.91% |
This slight downward trend highlights how Zosano Pharma Corp manages its efficiency in generating profits from shareholders' equity over time.
Comparing Zosano Pharma Corp's ROE (Return on Equity) to Peers
To better understand Zosano Pharma Corp's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Zosano Pharma Corp (ZSAN) | -90.75% |
| SQI Diagnostics Inc (SQD.V) | 188.78% |
| Titan Medical Inc (TMD.TO) | 145.31% |
| Sequana Medical NV (SEQUA.BR) | 100.62% |
| SANUWAVE Health Inc (SNWV) | 59.77% |
| IDEXX Laboratories Inc (IDXX) | 55.65% |
Compared to its competitors, Zosano Pharma Corp's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.